25. Thioridazine
26. Amtryptyline
27. Trifluperazine
28. Trimipramine
29. TriproKdine
30. Polymixin B. Sulphate
31. Glipizide
32. Pyrithyldione
33. Zinc Bacitracin
34. Mitomycin
35. Tolnefatate
36. Fluocinoloxe Acetoxide
37. Carbenicillin Sodium
38. Oxyfedrine Hcl
39. Hysoline N Butyl Bromide
40. Triamlinolone
41. Naproxen
42. Pyrithioxine
43. L-Dopa
44. Norgpsterol
45. Ethistarone
46. Carbenixolone
47. Reserpine.

Statement-II

S.No. Name of Bulk Drug

1. Cemetidine
2. Ranitidine
3. Amoxycillin
4. Ampicillin
5. Dexycycilline
6. Diphenoxylate
7. Hydralazine
8. Metoclopracide
9. Malidixic Acid
10. Promethazine
11. Timolol
12. Metroprolol
13. Chiorpromazine
14. Imiphamine
15. Povidone Iodine

Profitability of Drug Companies

465. SHRI RAJNI RANJAN SAHU:

SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that Government are monitoring the profitability of drug companies;

(b) if so, what was the profitability botl before tax and after tax of each of twenty fix major drug companies during the last thre years, year-wise;

(c) what was the total import of row materials and bulk drugs during the above period;

(d) what are the names of new bulk drugs .'or which production was started by each of those companies during his last three years and what 4 was the production of each, year-wise fro.m commencement of production; and

(e) what are the names of medicines for which any of these companies reduced prices during the above period ?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI EDUARDO FALEIRO): (a) and (b) Information as available of profit before tax of twenty five major drug companies is at Statement. *(See* below)

- (c) Company-wise imports are not monitored by the Government.

(d) To the extent information is available the details in regard to industrial Licenses granted for the production of new bulk drugs during last 3 years are as follows :

S. No.	Name of the Company	Name of New Bulk Drug	Date of issue of Industrial License	Capacity	Production
1	2	3	4	5	6
1.	E. Merck	Guaiazolene Crystals	6/91	10 Tonnes	Not yet Reported

2.	Roussel	Roxythromycin	11/92	60 Kg	-do-
3.	B. Mannheim	Verapamil Hcl	11/92	5 Tonnes	-do-

(e) Considering the large range of medicines, produced in various dosage forms and in varying pack sizes by these companies, the time and labour involved in the collection and compilation of the desired information would not be commensurate with the results likely to be achieved.

Statement

Profitability as reported in form-6 of DPCO, 87 in respect of 25 major companies

S. No.	Name of Company	Profit before tax as percentage of sales income during		
		1989-90	1990-91	1991-92
1.	Glaxo	4.3	3.9	2.1
2.	Ranbaxy	N.A.	N.A.	4.0
3.	Hoechst	3.5	2.2	N.A.
4.	Ciba Geigy	10.6	9.1	9.0
5.	Sandoz	5.0	4.5	3.9
6.	Procter & Gamble	6.4	3.3	4.8
7.	Burroughs Wellcome	2.7	3.8	2.5
8.	Bayer	6.0	8.2	8.3
9.	Pfizer	5.1 (12/88 to 3/90)	5.7	2.0
10.	Boots	N.A.	N.A.	8.0
11.	Parke Davis	5.6	6.0	5.6
12.	Alembic	1.8	0.6	(−) 1.2
13.	E. Merck*	4.5	2.2	(−) 1.8
14.	Reckit & Colman	17.4	19.0	16.7
15.	Cadila	N.A.	N.A.	2.9
16.	Cyanamid	10.2	10.9	11.10
17.	Nicholas	9.5	10.1	9.0
18.	SKF	14.6	14.3	16.1
19.	Dr. Reddy's Labs.	N.A.	6.1	12.0
20.	Rhone Poulenc	6.9	5.0	3.9
21.	Geoffrey Manners	5.8	3.8	4.9
22.	German Remedies	7.6	3.5	1.2
23.	Roussel	N.A.	N.A.	4.5
24.	Rallis	N.A.	N.A.	0.3
25.	Roche	2.8	0.8	0.7

* Figure pertain to calender year i.e. 1989. 1990. 1991.

NA.—Indicates-thai information is not available.